Omnicell (NASDAQ:OMCL) Shares Gap Up - What's Next?

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $27.34, but opened at $30.28. Omnicell shares last traded at $30.13, with a volume of 192,663 shares traded.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Bank of America upped their price objective on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday. Wall Street Zen upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a report on Tuesday, May 20th. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $37.00 price objective (up previously from $35.00) on shares of Omnicell in a research note on Friday. Piper Sandler reiterated an "overweight" rating on shares of Omnicell in a research report on Friday. Finally, JPMorgan Chase & Co. reduced their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, March 20th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $44.83.

Omnicell Trading Up 5.0%

The business's 50-day simple moving average is $30.81 and its 200-day simple moving average is $38.47. The company has a market cap of $1.39 billion, a PE ratio of 109.86, a P/E/G ratio of 7.53 and a beta of 0.78. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.10. The business had revenue of $269.67 million during the quarter, compared to analyst estimates of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Omnicell's quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the company earned $0.03 earnings per share. As a group, analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Omnicell

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Omnicell by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company's stock valued at $247,628,000 after buying an additional 28,573 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Omnicell by 10.1% in the first quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company's stock valued at $58,745,000 after acquiring an additional 154,038 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Omnicell by 31.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock worth $73,127,000 after acquiring an additional 394,820 shares in the last quarter. Lazard Asset Management LLC increased its stake in shares of Omnicell by 81.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock worth $73,093,000 after purchasing an additional 737,536 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Omnicell by 93.3% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock worth $64,573,000 after purchasing an additional 699,925 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.